Cochlear $11.6 B market cap, page-12

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 12 Last

Share
Profile

Follow
patto66

2,061 Posts.

386

15/09/18

01:11

Post #: 35616749
Share

Originally posted by Taurean7 ↑

This is the type of fundamental valuation exercise that any serious long-term investor should consider undertaking @pilko3 in order to inform their decisions to hold.

As mature businesses, Cochlear currently trades on a P/E ratio of 47.4 (MCap $11.66B, Earnings $246M) and Resmed on a ratio of 50.5 (MCap A$22.1B, Earnings A$438M). These companies have healthcare businesses comparable to ResApp, and so a P/E multiple of around 50 for the market to apply to RAP once profitable can be taken as appropriate.

This then indicates that each RAP earnings component of $10M p.a. would justify a market cap contribution of $500M. With 659M RAP shares currently on issue this translates to a 75.9 cents contribution to the share price.

So, taking future earnings of $100M as an example, a share price of $7.59 then would apply, with EPS of 15.2 cents. Applying a franked dividend payout ratio of 50%, net dividend would be 7.6c p.a., or a gross dividend of 10.9c per share allowing for franking contributions.

Your estimate of $1B p.a. earnings might require a few years to attain, but if so this would justify a share price of $75.90 should that be achieved, with a gross dividend annual of $1.09 per share.

The potential definitely is there.

Expand

I think though if Performance share and options are achieved the total register is closer to 800 million. Still the mind boggle at the potential numbers. But lets just get through the US trials first then let the speculation run wild.

RAP Price at posting: 27.0¢ Sentiment: Hold Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

EIQ

Echo IQ tests show heart failure can be detected in 86% of cases with AI

PEN

Peninsula promises restart of Lance uranium project in Wyoming by the end of 2024

MYE

Metarock falls -10% as QLD regulator takes it to court over 2021 death of Graham Dawson – after raiding company offices

Centuria Capital tops Wealth Within's stock picks

Is the ASX getting its groove back? Here's 5 IPOs in September to watch